JP2024525049A - Surface-modified retinoid-loaded porous silica - Google Patents
Surface-modified retinoid-loaded porous silica Download PDFInfo
- Publication number
- JP2024525049A JP2024525049A JP2023580832A JP2023580832A JP2024525049A JP 2024525049 A JP2024525049 A JP 2024525049A JP 2023580832 A JP2023580832 A JP 2023580832A JP 2023580832 A JP2023580832 A JP 2023580832A JP 2024525049 A JP2024525049 A JP 2024525049A
- Authority
- JP
- Japan
- Prior art keywords
- retinoid
- porous silica
- polyethoxylated
- loaded
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 198
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 129
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 99
- 239000002537 cosmetic Substances 0.000 claims abstract description 23
- 229910000077 silane Inorganic materials 0.000 claims abstract description 19
- -1 silane compound Chemical class 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 10
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002845 discoloration Methods 0.000 claims description 5
- MSRJTTSHWYDFIU-UHFFFAOYSA-N octyltriethoxysilane Chemical compound CCCCCCCC[Si](OCC)(OCC)OCC MSRJTTSHWYDFIU-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 229940100552 retinamide Drugs 0.000 claims description 4
- CPUDPFPXCZDNGI-UHFFFAOYSA-N triethoxy(methyl)silane Chemical compound CCO[Si](C)(OCC)OCC CPUDPFPXCZDNGI-UHFFFAOYSA-N 0.000 claims description 4
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000002981 blocking agent Substances 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 229940089951 perfluorooctyl triethoxysilane Drugs 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 150000004756 silanes Chemical class 0.000 claims description 3
- ALVYUZIFSCKIFP-UHFFFAOYSA-N triethoxy(2-methylpropyl)silane Chemical compound CCO[Si](CC(C)C)(OCC)OCC ALVYUZIFSCKIFP-UHFFFAOYSA-N 0.000 claims description 3
- AVYKQOAMZCAHRG-UHFFFAOYSA-N triethoxy(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane Chemical compound CCO[Si](OCC)(OCC)CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F AVYKQOAMZCAHRG-UHFFFAOYSA-N 0.000 claims description 3
- MLXDKRSDUJLNAB-UHFFFAOYSA-N triethoxy(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)silane Chemical compound CCO[Si](OCC)(OCC)CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F MLXDKRSDUJLNAB-UHFFFAOYSA-N 0.000 claims description 3
- FZMJEGJVKFTGMU-UHFFFAOYSA-N triethoxy(octadecyl)silane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OCC)(OCC)OCC FZMJEGJVKFTGMU-UHFFFAOYSA-N 0.000 claims description 3
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000010696 ester oil Substances 0.000 claims description 2
- MASNVFNHVJIXLL-UHFFFAOYSA-N ethenyl(ethoxy)silicon Chemical compound CCO[Si]C=C MASNVFNHVJIXLL-UHFFFAOYSA-N 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000004611 light stabiliser Substances 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 claims description 2
- FWDBOZPQNFPOLF-UHFFFAOYSA-N ethenyl(triethoxy)silane Chemical compound CCO[Si](OCC)(OCC)C=C FWDBOZPQNFPOLF-UHFFFAOYSA-N 0.000 claims 1
- 238000004381 surface treatment Methods 0.000 abstract description 9
- 238000013268 sustained release Methods 0.000 abstract description 9
- 239000012730 sustained-release form Substances 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 3
- 239000000843 powder Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 15
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000037384 skin absorption Effects 0.000 description 7
- 231100000274 skin absorption Toxicity 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012756 surface treatment agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本発明は、表面改質されたレチノイド担持多孔性シリカに関し、より詳細には、本発明は、ポリエトキシル化形態のレチノイドを多孔性シリカに担持した後、シラン系化合物で表面処理することによって、レチノイドの担持効率を高め、徐放性放出効率を改善し、安定性と安全性が改善された機能性化粧品の有効成分として活用することができる。The present invention relates to a surface-modified retinoid-loaded porous silica, and more particularly, the present invention relates to a method for loading a polyethoxylated retinoid onto a porous silica, followed by surface treatment with a silane compound, thereby increasing the loading efficiency of the retinoid, improving the sustained release efficiency, and enabling the product to be used as an active ingredient in functional cosmetics with improved stability and safety.
Description
本発明は、安定性および安全性が改善された低刺激の表面改質されたレチノイド担持多孔性シリカに関する。 The present invention relates to a surface-modified retinoid-loaded porous silica that is hypoallergenic and has improved stability and safety.
ビタミンAあるいはその誘導体は、現在まで知られた老化皮膚改善の代表的な物質であり、これらを含有する製品が多く販売されている。ビタミンAあるいはその誘導体は、皮膚内線維芽細胞の増殖およびコラーゲン合成を増殖させることが知られており、シワ機能性化粧品の有効成分として多様に活用されている。しかしながら、ビタミンAは、脂溶性であり、光、酸素、熱、脂質過酸化物により不安定であるという短所があり、安定化技術が必須であり、製品開発時に、容器についても、光と酸素が遮断される容器を使用することが、安定性を確保することができる。また、過量のビタミンAあるいはその誘導体は、日光によって皮膚感受性を増加させることができる物質である。消費者がビタミンAあるいはその誘導体が含まれる化粧品を使用する場合、皮膚において皮膚の発赤、紅斑、痛み、かゆみなどの多様な形態で皮膚に発現する。 Vitamin A or its derivatives are representative substances known to date for improving aging skin, and many products containing them are on the market. Vitamin A or its derivatives are known to promote the proliferation of fibroblasts in the skin and collagen synthesis, and are used in a variety of ways as active ingredients in wrinkle-fighting functional cosmetics. However, vitamin A is fat-soluble and has the disadvantage of being unstable due to light, oxygen, heat, and lipid peroxides, so stabilization technology is essential, and stability can be ensured by using containers that block light and oxygen during product development. In addition, excessive amounts of vitamin A or its derivatives are substances that can increase skin sensitivity due to sunlight. When consumers use cosmetics containing vitamin A or its derivatives, various symptoms such as redness, erythema, pain, and itching can appear on the skin.
このようなビタミンAおよびその誘導体の安定性および安全性の改善のために、韓国登録特許(10-1314100)等においてリポソームなどの様々な薬物伝達システムを用いて安定性/安全性を改善するために努力している。しかしながら、このような薬物伝達支持体は、有効成分の担持効率が顕著に低いだけでなく、化粧品剤形内で他の補助成分および剤形製造工程中で薬物伝達支持体の形態が一時的に崩壊あるいは一部が崩壊される現象が発生する。これによって、レチノイドの安定性改善効果が大きくなく、徐放性放出によって引き起こされる安全性改善効果も依然として不十分である。 In order to improve the stability and safety of vitamin A and its derivatives, efforts have been made to improve stability/safety by using various drug delivery systems such as liposomes in Korean patent (10-1314100) and other documents. However, such drug delivery supports not only have a significantly low carrying efficiency of the active ingredient, but also cause a phenomenon in which the form of the drug delivery support temporarily collapses or is partially collapsed during the manufacturing process of the formulation and other auxiliary ingredients in the cosmetic formulation. As a result, the effect of improving the stability of retinoids is not significant, and the effect of improving safety caused by sustained release is still insufficient.
本発明の目的は、安定性/安全性が改善された低刺激のレチノイド担持多孔性シリカおよびその製造方法を提供することにある。 The object of the present invention is to provide a low-irritation retinoid-loaded porous silica with improved stability/safety and a method for producing the same.
本発明の他の目的は、前記低刺激のレチノイド担持多孔性シリカを含む化粧料組成物を提供することにある。 Another object of the present invention is to provide a cosmetic composition containing the low-irritation retinoid-loaded porous silica.
上記目的を達成するために、本発明は、ポリエトキシル化レチノイドが担持され、シラン系化合物により表面改質されたレチノイド担持多孔性シリカを提供する。 To achieve the above object, the present invention provides a retinoid-loaded porous silica that is loaded with a polyethoxylated retinoid and has its surface modified with a silane compound.
本発明は、また、ポリエトキシル化レチノイド溶液および多孔性シリカを混合し、多孔性シリカ内にポリエトキシル化レチノイドを担持する段階と、
ポリエトキシル化レチノイドが担持された多孔性シリカおよびシラン系化合物を反応させて、多孔性シリカの表面を改質する段階と、を含む表面改質されたレチノイド担持多孔性シリカの製造方法を提供する。
The present invention also provides a method for preparing a composition comprising the steps of: mixing a polyethoxylated retinoid solution and a porous silica to load the polyethoxylated retinoid within the porous silica;
and reacting the porous silica carrying a polyethoxylated retinoid with a silane-based compound to modify the surface of the porous silica.
本発明は、また、前記の表面改質されたレチノイド担持多孔性シリカを含む化粧料組成物を提供する。 The present invention also provides a cosmetic composition containing the surface-modified retinoid-loaded porous silica.
本発明は、ポリエトキシル化形態のレチノイドを多孔性シリカに担持した後、シラン系化合物で表面処理することによって、レチノイドの担持効率を高め、徐放性放出効率を改善し、安定性と安全性が改善された機能性化粧品の有効成分として活用することができる。 The present invention involves supporting a polyethoxylated form of retinoid on porous silica, followed by surface treatment with a silane compound, thereby increasing the retinoid supporting efficiency, improving sustained release efficiency, and enabling the product to be used as an active ingredient in functional cosmetics with improved stability and safety.
以下、本発明の構成を具体的に説明する。 The configuration of the present invention is explained in detail below.
本発明は、ポリエトキシル化レチノイドが担持され、シラン系化合物によって表面改質されたレチノイド担持多孔性シリカに関する。 The present invention relates to a retinoid-loaded porous silica that is loaded with a polyethoxylated retinoid and has its surface modified with a silane-based compound.
本発明は、ビタミンA誘導体であるレチノイドの1)安定性を改善するために、化粧品剤形内で他の成分によって分解/変性が容易に起こらず、レチノイド類の光/酸素の露出を減少させて安定性を向上させることができ、他の薬物伝達支持体と比較して、高含有量のレチノイドを担持できる長所を担体として多孔性シリカを使用し、2)レチノイド安全性を改善するために、多孔性シリカの表面をシラン系化合物で表面処理することによって、徐放性でレチノイドを溶出させることを特徴とする。 The present invention is characterized by the use of porous silica as a carrier, which has the advantages of being less susceptible to decomposition/denaturation by other ingredients in a cosmetic formulation, improving stability by reducing exposure of retinoids to light/oxygen, and being able to support a high amount of retinoid compared to other drug delivery supports, in order to 1) improve the stability of retinoid, which is a vitamin A derivative, and by treating the surface of the porous silica with a silane compound to allow the retinoid to be released in a sustained manner, in order to improve the safety of the retinoid.
本発明の一具体例によれば、レチノイドの放出挙動は、O/W剤形に本発明の表面改質されたレチノイド担持多孔性シリカと多孔性シリカに担持しないレチノイドをフランツ拡散セル(Franze diffusion cell)を用いて比較し、レチノイドの安全性を比較するためには、表面改質されたレチノイド担持多孔性シリカパウダーのHET-CAMテストおよび消費者品評を通じて刺激指数を確認した。その結果、25℃および40℃で表面改質されたレチノイド担持多孔性シリカパウダー適用剤形は、16週でも安定しており、シラン系化合物の濃度依存的にレチノイド溶出量が減少し、レチノイドを徐々に溶出させることによって、徐放性製剤としての応用可能性を確認した。 According to one embodiment of the present invention, the release behavior of retinoid was compared using a Franz diffusion cell between the surface-modified retinoid-loaded porous silica of the present invention and a retinoid not loaded on porous silica in an O/W formulation, and the irritation index was confirmed through a HET-CAM test and consumer evaluation of the surface-modified retinoid-loaded porous silica powder to compare the safety of the retinoid. As a result, the formulation in which the surface-modified retinoid-loaded porous silica powder was applied at 25°C and 40°C was stable even after 16 weeks, and the amount of retinoid eluted decreased depending on the concentration of the silane compound, confirming the possibility of application as a sustained-release formulation by gradually eluting the retinoid.
前記ポリエトキシル化レチノイドは、ポリエトキシル化レチナミド(polyethoxylated retinamide)を使用することができる。 The polyethoxylated retinoid may be polyethoxylated retinamide.
前記多孔性シリカは、1~50μmの直径サイズを有することができる。 The porous silica may have a diameter size of 1 to 50 μm.
前記シラン系化合物は、トリエトキシカプリリルシラン(Triethoxycaprylylsilane)、アミノプロピルトリエトキシシラン(Aminopropyl Triethoxysilane)、グリシドキシプロピルトリメトキシシラン(Glycidoxypropyl Trimethoxysilane)、イソブチルトリエトキシシラン(Isobutyltriethoxysilane)、ペルフルオロオクチルエチルトリエトキシシラン(Perfluorooctylethyl Triethoxysilane)、ペルフルオロオクチルトリエトキシシラン(Perfluorooctyl Triethoxysilane)、ステアリルトリエトキシシラン(Stearyl Triethoxysilane)、メチルトリエトキシシラン(Methyltriethoxysilane)、PEG-8メチルエーテルトリエトキシシラン(PEG-8 Methyl Ether Triethoxysilane)、ビニルエトキシシラン(Vinyltriethoxysilane)等を単独または2種以上使用することができる。 The silane compounds include triethoxycaprylylsilane, aminopropyl triethoxysilane, glycidoxypropyl trimethoxysilane, isobutyl triethoxysilane, perfluorooctylethyl triethoxysilane, perfluorooctyl triethoxysilane, and stearyl triethoxysilane. Triethoxysilane), methyltriethoxysilane, PEG-8 methyl ether triethoxysilane, vinylethoxysilane, etc. can be used alone or in combination of two or more.
本発明は、また、ポリエトキシル化レチノイド溶液および多孔性シリカを混合し、多孔性シリカ内にポリエトキシル化レチノイドを担持する段階と、
ポリエトキシル化レチノイドが担持された多孔性シリカおよびシラン系化合物を反応させて、多孔性シリカの表面を改質する段階と、を含む表面改質されたレチノイド担持多孔性シリカの製造方法に関する。
The present invention also provides a method for preparing a composition comprising the steps of: mixing a polyethoxylated retinoid solution and a porous silica to load the polyethoxylated retinoid within the porous silica;
and reacting the porous silica carrying a polyethoxylated retinoid with a silane-based compound to modify the surface of the porous silica.
本発明の表面改質されたレチノイド担持多孔性シリカは、ペグ化によって親水部を有するレチノイドを多孔性シリカに担持させた後、熱処理を通じて疎水性のシラン系化合物で表面コーティングすることによって製造されることを特徴とする。 The surface-modified retinoid-loaded porous silica of the present invention is characterized in that it is produced by loading a retinoid having a hydrophilic portion onto porous silica by PEGylation, and then surface-coating the silica with a hydrophobic silane compound through heat treatment.
本発明の表面改質されたレチノイド担持多孔性シリカの製造方法を段階別に具体的に説明すれば、次の通りである。 The method for producing the surface-modified retinoid-loaded porous silica of the present invention is described in detail below.
第1段階は、ポリエトキシル化レチノイドを多孔性シリカに担持させる段階である。 The first step is to support the polyethoxylated retinoid onto the porous silica.
このために、まず、ポリエトキシル化レチノイドを光遮断条件で溶媒に均等に溶解させて、レチノイド溶液を製造する。 To this end, first, a polyethoxylated retinoid is uniformly dissolved in a solvent under light-blocking conditions to prepare a retinoid solution.
前記ポリエトキシル化レチノイドは、表面改質されたレチノイド担持多孔性シリカ100重量%に対して0.5~20重量%、さらに具体的には、5~15重量%で混合することができる。前記範囲から外れる場合、多孔性シリカ内に担持されずに残留するレチノイド含有量が増加し、経済性が低下することがある。 The polyethoxylated retinoid can be mixed at 0.5 to 20% by weight, more specifically 5 to 15% by weight, relative to 100% by weight of the surface-modified retinoid-loaded porous silica. Outside this range, the amount of retinoid remaining unloaded in the porous silica increases, which can reduce economic efficiency.
前記溶媒は、メタノールまたはエタノールを使用することができる。前記溶媒の含有量は、レチノイドの含有量によって当業者レベルで適宜調節することができ、特に限定されない。 The solvent may be methanol or ethanol. The content of the solvent is not particularly limited and can be adjusted by those skilled in the art depending on the content of the retinoid.
前記レチノイド溶液の製造時に、必要に応じてハイドロカーボン系オイル、エステルオイル、天然オイル、シリコーンオイル、抗酸化剤、光安定剤、抗炎症剤、変色防止剤、紫外線遮断剤、染料、顔料などをさらに添加することができる。 When preparing the retinoid solution, hydrocarbon oils, ester oils, natural oils, silicone oils, antioxidants, light stabilizers, anti-inflammatory agents, discoloration inhibitors, UV blocking agents, dyes, pigments, etc. can be further added as necessary.
次に、多孔性シリカにポリエトキシル化レチノイド溶液を徐々に投入し、ミキサー、例えば、ヘンシェルミキサーなどを用いて常温で10分以上均等に混ぜる。 Next, gradually add the polyethoxylated retinoid solution to the porous silica and mix evenly at room temperature for at least 10 minutes using a mixer, such as a Henschel mixer.
前記多孔性シリカは、1~50μmの直径サイズを有することができる。前記多孔性シリカのオイル吸油量は、0.3~3cc/gレベルの原料を使用することができる。前記多孔性シリカは、表面改質されたレチノイド担持多孔性シリカ100重量%に対して50~99重量%、好ましくは、60~99重量%、より好ましくは、65~94重量%で混合することができる。前記範囲から外れる場合、多孔性シリカパウダーが均一な粉末状とならず、塊状として製造され得る。これは、他の化粧品剤形に分散させたとき、安定性に影響を及ぼす恐れがある。 The porous silica may have a diameter size of 1 to 50 μm. The porous silica may have an oil absorption of 0.3 to 3 cc/g. The porous silica may be mixed at 50 to 99% by weight, preferably 60 to 99% by weight, more preferably 65 to 94% by weight, relative to 100% by weight of the surface-modified retinoid-loaded porous silica. Outside this range, the porous silica powder may not be a uniform powder, but may be produced in clumps. This may affect stability when dispersed in other cosmetic formulations.
第2段階は、表面処理(改質)剤としてシラン系化合物を使用してポリエトキシル化レチノイドが担持された多孔性シリカの表面を改質する段階である。 The second step is to modify the surface of the porous silica carrying the polyethoxylated retinoid using a silane-based compound as a surface treatment (modification) agent.
第1段階で製造されたポリエトキシル化レチノイドが担持された多孔性シリカにシラン系化合物を投入し、ヘンシェルミキサーを用いて約10分間均等に混ぜる。次に、表面処理のために40~120℃で30分~5時間、さらに具体的には、80~100℃で1時間~4時間反応させる熱処理を行った後、冷却させて、表面改質されたレチノイド担持多孔性シリカを製造する。熱処理が前記範囲から外れる場合、低温では、表面処理が十分に進行されないことがあり、高温の場合、レチノイド変色およびその他物質の安定性に影響を及ぼす恐れがある。 A silane compound is added to the polyethoxylated retinoid-loaded porous silica produced in the first step, and the mixture is mixed evenly for about 10 minutes using a Henschel mixer. Next, for surface treatment, heat treatment is carried out at 40-120°C for 30 minutes to 5 hours, or more specifically, at 80-100°C for 1 hour to 4 hours, and then cooled to produce surface-modified retinoid-loaded porous silica. If the heat treatment is outside the above range, low temperatures may not sufficiently advance the surface treatment, and high temperatures may cause discoloration of the retinoid and affect the stability of other substances.
前記シラン系化合物は、表面改質されたレチノイド担持多孔性シリカ100重量%に対して0.5~20重量%、さらに具体的には、1~15重量%で混合することができる。前記範囲から外れる場合、レチノイド溶出量が減少し、レチノイドの効果が減少したり、非常に過量の場合、多孔性シリカの内部に捕集されずにシリカの表面に存在することがある。 The silane compound can be mixed at 0.5 to 20% by weight, more specifically 1 to 15% by weight, relative to 100% by weight of the surface-modified retinoid-loaded porous silica. Outside this range, the amount of retinoid eluted may decrease, reducing the effect of the retinoid, or in the case of an extremely excessive amount, the retinoid may remain on the surface of the silica rather than being captured inside the porous silica.
本発明は、また、前記の表面改質されたレチノイド担持多孔性シリカを含む化粧料組成物に関する。 The present invention also relates to a cosmetic composition containing the surface-modified retinoid-loaded porous silica.
レチノイドは、皮膚内線維芽細胞の増殖およびコラーゲン合成を増殖させるので、本発明の化粧料組成物は、シワ機能性化粧品に使用され得る。 Since retinoids stimulate the proliferation of dermal fibroblasts and collagen synthesis, the cosmetic composition of the present invention can be used in wrinkle-fighting functional cosmetics.
また、本発明の表面改質されたレチノイド担持多孔性シリカは、O/W剤形にパウダー形態で使用され得る。本発明の表面改質されたレチノイド担持多孔性シリカは、化粧料組成物100重量%に対して0.01~5重量%、さらに具体的には、0.05~4重量%で含まれ得る。前記範囲から外れる場合、レチノイドの効果が不十分であるか、過量使用により安定性および安全性に影響を及ぼす恐れがある。 The surface-modified retinoid-loaded porous silica of the present invention may also be used in the form of a powder in an O/W formulation. The surface-modified retinoid-loaded porous silica of the present invention may be included in an amount of 0.01 to 5% by weight, more specifically 0.05 to 4% by weight, based on 100% by weight of the cosmetic composition. Outside this range, the effect of the retinoid may be insufficient, or excessive use may affect stability and safety.
本発明の化粧料組成物は、一般的な乳化剤形または可溶化剤形の化粧品形態で製造することができる。例えば、柔軟化粧水または栄養化粧水などのような化粧水、フェイシャルローション、ボディローションなどのような乳液、栄養クリーム、水分クリーム、アイクリームなどのようなクリーム、エッセンス、化粧軟膏、スプレー、ゼル、パック、サンスクリーン、メイクアップベース、液体タイプ、固体タイプまたはスプレータイプなどのファンデーション、パウダー、クレンジングクリーム、クレンジングローション、クレンジングオイルのようなメイクアップ除去剤、クレンジングフォーム、せっけん、ボディウォッシュなどのような洗浄剤などの剤形を有することができる。 The cosmetic composition of the present invention can be prepared in the form of a cosmetic product in the general emulsion or solubilization form. For example, it can have the form of a lotion such as a softening lotion or a nutritious lotion, a milky lotion such as a facial lotion or a body lotion, a cream such as a nutritious cream, a moisture cream, or an eye cream, an essence, a cosmetic ointment, a spray, a gel, a pack, a sunscreen, a makeup base, a liquid type, a solid type, or a spray type foundation, a powder, a makeup remover such as a cleansing cream, a cleansing lotion, or a cleansing oil, or a cleansing agent such as a cleansing foam, a soap, or a body wash.
また、本発明の化粧料組成物は、一般的な化粧料組成物の製造時に使用する補助成分として脂肪物質、有機溶媒、溶解剤、濃縮剤およびゲル化剤、軟化剤、抗酸化剤、懸濁化剤、安定化剤、発泡剤(foaming agent)、芳香剤、界面活性剤、水、イオン型または非イオン型乳化剤、充填剤、金属イオン封鎖剤およびキレート化剤、保存剤、ビタミン、遮断剤、湿潤化剤、必須オイル、染料、顔料、親水性または親油性活性剤、脂質小胞または化粧品に通常使用される任意の他の成分のような化粧品学分野において通常使用される補助剤を含有することができる。 The cosmetic composition of the present invention may also contain auxiliary ingredients commonly used in the field of cosmetology, such as fatty substances, organic solvents, solubilizers, thickening and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, moisturizing agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics, as auxiliary ingredients commonly used in the preparation of cosmetic compositions.
本発明の一具体例によれば、本発明の表面改質されたレチノイド担持多孔性シリカは、O/W剤形にパウダー形態で使用され得、O/W剤形は、下記表2の組成によって75℃で油相および水相成分を完全に溶解させた後、ホモミキサーを用いて一次乳化させ、本発明の表面改質されたレチノイド担持多孔性シリカパウダーを45℃で投入して、二次乳化させて製造することができる。 According to one embodiment of the present invention, the surface-modified retinoid-loaded porous silica of the present invention can be used in the form of a powder in an O/W formulation, which can be prepared by completely dissolving the oil phase and water phase components at 75°C according to the composition in Table 2 below, followed by primary emulsification using a homomixer, and then adding the surface-modified retinoid-loaded porous silica powder of the present invention at 45°C for secondary emulsification.
以下、本発明による実施例に基づいて本発明をより詳細に説明するが、本発明の範囲が下記提示された実施例によって制限されるものではない。 The present invention will be described in more detail below based on examples of the present invention, but the scope of the present invention is not limited to the examples presented below.
<実施例1>~<実施例4>表面改質されたレチノイド担持多孔性シリカパウダーの製造および適用剤形
表面改質されたレチノイド担持多孔性シリカの製造のためのレチノイドは、ポリエトキシル化レチナミドを使用した。表1の組成のように、レチノイドおよびエタノールを光遮断条件で均一に溶解させた後、ヘンシェルミキサーを用いて多孔性シリカに作成されたレチノイド溶液を徐々に投入し、10分間均等に混ぜた。多孔性シリカのサイズは、1~50μmの直径を使用し、多孔性シリカのオイル吸油量は、0.3~3cc/gレベルの原料を使用した。一次に作成されたパウダーにトリエトキシカプリリルシラン(triethoxycaprylylsilane)を投入し、ヘンシェルミキサーを用いて10分間均等に混ぜた。表面処理のために、約100℃で4時間反応させて、表面処理反応を実施した後、冷却して、最終表面改質されたレチノイド担持多孔性シリカパウダーを得た。
<Examples 1> to <Example 4> Preparation of surface-modified retinoid-loaded porous silica powder and application form Polyethoxylated retinamide was used as the retinoid for preparing the surface-modified retinoid-loaded porous silica. As shown in the composition in Table 1, the retinoid and ethanol were uniformly dissolved under light-blocking conditions, and the retinoid solution prepared was gradually added to the porous silica using a Henschel mixer and mixed evenly for 10 minutes. The porous silica used had a diameter of 1 to 50 μm and a porous silica oil absorption of 0.3 to 3 cc/g. Triethoxycaprylylsilane was added to the powder prepared in the first step and mixed evenly for 10 minutes using a Henschel mixer. For the surface treatment, the mixture was reacted at about 100° C. for 4 hours to carry out the surface treatment reaction, and then cooled to obtain the final surface-modified retinoid-loaded porous silica powder.
作成されたレチノイド担持多孔性シリカパウダーを実際O/W剤形に適用し、組成は、表2の通りである。製造方法は、75℃で油相および水相を完全に溶解させた後、ホモミキサーを用いて一次乳化して製造し、レチノイドおよびレチノイド多孔性シリカパウダーは、45℃で投入後、二次乳化を進めた。 The retinoid-loaded porous silica powder thus prepared was applied to an actual O/W formulation, and the composition is shown in Table 2. The production method was as follows: the oil phase and the water phase were completely dissolved at 75°C, and then the primary emulsification was carried out using a homomixer. The retinoid and retinoid porous silica powder were added at 45°C, and the secondary emulsification was carried out.
本発明において使用されたレチノイドは、(株)エルエスケムで製造されたMedimin A(平均分子量831)を用い、多孔性シリカは、センジンビューティーサイエンス社製のsunsil-130、表面処理剤は、信越社のAES原料、レチノールは、BASF社のRetinol 50Cを使用した。 The retinoid used in this invention was Medimin A (average molecular weight 831) manufactured by LS-Chem Co., Ltd., the porous silica was sunsil-130 manufactured by Sendin Beauty Science Co., Ltd., the surface treatment agent was AES raw material manufactured by Shin-Etsu Co., Ltd., and the retinol was Retinol 50C manufactured by BASF Corporation.
<実験例1>レチノール/レチノイド変色比較実験
ポリエトキシル化レチノイドが担持された多孔性シリカ(実施例3)にシラン系化合物を投入し、ヘンシェルミキサーを用いて均等に分散させた後、熱処理温度条件で4時間反応させた後に得られたパウダーは、下記の通りである。比較例3のように、レチノールの場合、熱処理時に変色が生じたのに対し、実施例3の場合、熱処理温度100℃で淡黄色のパウダーが得られた。一方、130℃以上の高温で熱処理を進める場合、橙色のパウダーが得られる。
Experimental Example 1: Comparative experiment of retinol/retinoid discoloration A silane compound was added to the porous silica carrying polyethoxylated retinoid (Example 3), uniformly dispersed using a Henschel mixer, and reacted for 4 hours under heat treatment temperature conditions to obtain the powder shown below. As in Comparative Example 3, discoloration occurred during heat treatment in the case of retinol, whereas in Example 3, a pale yellow powder was obtained at a heat treatment temperature of 100°C. Meanwhile, when heat treatment was performed at a high temperature of 130°C or higher, an orange powder was obtained.
<実験例2>レチノイド安定性改善効果
レチノイドの安定性を確認するために、純粋レチノイド(比較例4)、レチノイド担持多孔性シリカパウダー適用剤形(比較例5)、表面改質されたレチノイド担持多孔性シリカパウダー適用剤形(実施例4)に対して経時的な力価分析を実施した。
Experimental Example 2: Effect of improving retinoid stability In order to confirm the stability of retinoid, a time-dependent potency analysis was carried out on a pure retinoid (Comparative Example 4), a formulation containing a retinoid-loaded porous silica powder (Comparative Example 5), and a formulation containing a surface-modified retinoid-loaded porous silica powder (Example 4).
表4に示されたように、比較例4<比較例5=実施例4の順に安定性が改善されることを確認することができた。 As shown in Table 4, it was confirmed that the stability improved in the following order: Comparative Example 4 < Comparative Example 5 = Example 4.
<実験例3>安全性改善のための徐放性薬物伝達体としてのレチノイド溶出挙動実験(溶媒条件別のレチノイド溶出挙動実験)
レチノイドの放出挙動を調べるために、比較例2および実施例1~3を化粧品で頻繁に使用する溶媒を用いて一次的に溶出実験を実施した。溶媒としては、1,3-ブチレングリコール(1,3-butylene glycol)を使用し、比較例2および実施例1~3のパウダーを溶媒に5%分散させた後、1週間振とう培養器(shaking incubator)で1週間溶出させた。1週後、溶媒の上澄み液のみを分析し、溶出量を計算した。
<Experimental Example 3> Experiment on the dissolution behavior of retinoid as a sustained release drug delivery agent for improving safety (Experiment on the dissolution behavior of retinoid under different solvent conditions)
To investigate the release behavior of retinoid, a primary dissolution experiment was carried out for Comparative Example 2 and Examples 1 to 3 using a solvent that is frequently used in cosmetics. 1,3-butylene glycol was used as the solvent, and the powders of Comparative Example 2 and Examples 1 to 3 were dispersed in the solvent at 5% and then allowed to dissolve for one week in a shaking incubator. After one week, only the supernatant of the solvent was analyzed, and the amount of dissolution was calculated.
表5に示されたように、表面処理が施されていない比較例2の場合、レチノイドが全部溶出され、表面処理された実施例1~3の場合、徐放性薬物伝達体で徐々にレチノイドを溶出させることを確認することができた。また、トリエトキシカプリリルシランの濃度依存的に(2~7%)レチノイドの溶出量が減少し、これを通じて、表面改質されたレチノイド多孔性シリカパウダーが徐放性製剤として応用可能性があることを確認した。 As shown in Table 5, in the case of Comparative Example 2 where no surface treatment was performed, all of the retinoid was dissolved, while in the case of Examples 1 to 3 where surface treatment was performed, it was confirmed that the retinoid was gradually dissolved from the sustained-release drug delivery medium. In addition, the amount of retinoid dissolved was reduced depending on the concentration of triethoxycaprylylsilane (2 to 7%), and it was confirmed that the surface-modified retinoid porous silica powder can be used as a sustained-release formulation.
(O/W剤形におけるレチノイド放出挙動実験)
実際化粧品剤形におけるレチノイド溶出挙動および皮膚透過を確認するために、比較例4の剤形と溶出量の最も低い実施例3を適用した実施例4の剤形をフランツ拡散セル(Franze diffusion cell)実験を通じて比較した。皮膚透過装置は、図示のような装置を使用し、皮膚透過装置は、ドナー室(donor chamber)とレセプター室(receptor chamber)で構成されていて、これらの間に皮膚を位置させた後、固定した(図2参照)。同じ試験に使用する各セルは、2.54cm2の同じ表面積を有する。準備した皮膚は、角質層(stratum corneum)が上部に位置するようにして、皮膚透過装置に固定する。レセプター室の水溶液の量は、2.4mLであり、試験物質の拡散に影響を与えないように300rpmで撹拌した。本試験でのレチノイドの濃度は、196.85μg/cm2に定めて使用した。皮膚内最大吸収率を維持するために適用する剤形の量は、39.370μl/cm2にして一定の皮膚吸収状態を維持し、皮膚の上に均等に塗布した。試験物質の塗布後、6時間/24時間実験が終了した時点に皮膚を採取し、皮膚吸収率を把握した。
(Retinoid release behavior experiment in O/W formulation)
In order to confirm the retinoid dissolution behavior and skin permeation in the actual cosmetic formulation, the formulation of Comparative Example 4 and the formulation of Example 4, which applied Example 3 with the lowest dissolution amount, were compared through a Franz diffusion cell experiment. The skin permeation device used was as shown in the figure, and the skin permeation device was composed of a donor chamber and a receptor chamber, and the skin was placed between them and then fixed (see FIG. 2). Each cell used in the same test has the same surface area of 2.54 cm2. The prepared skin is fixed to the skin permeation device with the stratum corneum located at the top. The amount of aqueous solution in the receptor chamber was 2.4 mL, and it was stirred at 300 rpm so as not to affect the diffusion of the test substance. The concentration of retinoid used in this test was set to 196.85 μg/ cm2 . The amount of the formulation applied to maintain the maximum absorption rate in the skin was 39.370 μl/ cm2 to maintain a constant skin absorption state and to apply evenly on the skin. After application of the test substance, the skin was sampled at the end of the 6-hour/24-hour experiment to determine the skin absorption rate.
表6と表7および図3と図4のように、6時間皮膚吸収量を比較したとき、比較例4と比較して、実施例4は、徐放性薬物伝達体で溶出されるレチノイドの含有量が小さいが、24時間皮膚吸収量の比較結果、多孔性シリカに担持しないレチノイドと同一量吸収されることを確認した。したがって、徐放性製剤で実施例4がレチノイドを徐々に溶出するが、多孔性シリカに担持しないレチノイドと同様のレベルで吸収され、同じ効能/効果を示すことができることを確認することができた。 As shown in Tables 6 and 7 and Figures 3 and 4, when comparing the 6-hour skin absorption amount, Example 4 had a smaller amount of retinoid dissolved from the sustained-release drug delivery agent than Comparative Example 4, but the comparison of the 24-hour skin absorption amount confirmed that the same amount was absorbed as retinoid not supported in porous silica. Therefore, it was confirmed that Example 4 gradually releases retinoid in the sustained-release formulation, but is absorbed at the same level as retinoid not supported in porous silica, and can exhibit the same efficacy/effect.
<実験例4>レチノイド担持多孔性シリカパウダーの安全性改善効果(In vitro HET-CAMテスト)
有精卵の眼粘膜刺激可能性評価によって安全性改善効果を調べた。使用された有精卵の種および系統は、白色レグホン(white leghorn,white egg)である。有精卵の感度を点検するために、基準物質であるテキサポン(Texapon)を用いて予備実験を行い、出血および溶血程度を把握し、実験群と比較した。刺激判断の基準は、弱い刺激性(slightly irritating)、中等度の刺激性(moderately irritating)、刺激性(irritating)、強い刺激性(severely irritating)に分けて評価した。表面改質されたレチノイド担持多孔性シリカパウダーの安全性を確認するために、比較例1、実施例3のサンプルにHET-CAMテストを進めた。
<Experimental Example 4> Safety improvement effect of retinoid-loaded porous silica powder (In vitro HET-CAM test)
The safety improvement effect was examined by evaluating the possibility of ocular mucosa irritation of fertilized eggs. The species and lineage of fertilized eggs used were white leghorn (white egg). In order to check the sensitivity of fertilized eggs, a preliminary experiment was conducted using a reference material, Texapon, to grasp the degree of bleeding and hemolysis and compare it with the experimental group. The criteria for irritation judgment were divided into slightly irritating, moderately irritating, irritating, and severely irritating. In order to confirm the safety of the surface-modified retinoid-loaded porous silica powder, the samples of Comparative Example 1 and Example 3 were subjected to HET-CAM tests.
表8に示されたように、多孔性シリカ担持および表面改質された実施例3のサンプルの刺激指数が、比較例1の刺激指数に比べて低いことを確認した。 As shown in Table 8, it was confirmed that the irritation index of the porous silica-supported and surface-modified sample of Example 3 was lower than that of Comparative Example 1.
(In vivo消費者品評テスト)
表面改質されたレチノイド多孔性シリカパウダーの安全性改善効果を調べるために、比較例5と実施例4のサンプルを用いて消費者刺激品評テストを進めた。品評は、女性消費者25人を対象に夕方に1回使用し、1週間使用した後、最終刺激品評を進めた。刺激品評の尺度は、5段階評価で行い、点数が大きくなるほど刺激の強度が強くなることを意味する。
(In vivo consumer evaluation test)
In order to examine the safety improvement effect of the surface-modified retinoid porous silica powder, a consumer irritation evaluation test was conducted using the samples of Comparative Example 5 and Example 4. The evaluation was conducted on 25 female consumers, who used the powder once in the evening for one week, and then a final irritation evaluation was conducted after one week of use. The irritation evaluation was conducted on a 5-point scale, with the higher the score, the stronger the intensity of irritation.
図5に示されたように、比較例5および実施例4が両方とも2点以下であり、刺激が弱いことが分かった。 As shown in Figure 5, both Comparative Example 5 and Example 4 were scored below 2 points, indicating that they were less irritating.
本発明は、安定性と安全性が改善された機能性化粧品分野に適用することができる。 The present invention can be applied to the field of functional cosmetics with improved stability and safety.
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0084952 | 2021-06-29 | ||
KR1020210084952A KR102697264B1 (en) | 2021-06-29 | 2021-06-29 | Surface modified retinoid immersion porous silica |
PCT/KR2022/009120 WO2023277479A1 (en) | 2021-06-29 | 2022-06-27 | Surface-modified retinoid-impregnated porous silica |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024525049A true JP2024525049A (en) | 2024-07-09 |
Family
ID=84692900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023580832A Pending JP2024525049A (en) | 2021-06-29 | 2022-06-27 | Surface-modified retinoid-loaded porous silica |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2024525049A (en) |
KR (1) | KR102697264B1 (en) |
CN (1) | CN115531230A (en) |
TW (1) | TW202317065A (en) |
WO (1) | WO2023277479A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100589957B1 (en) * | 1998-12-31 | 2007-04-25 | 주식회사 엘지생활건강 | Anti-aging cosmetic composition containing polyethoxylated retinamide |
KR100768113B1 (en) * | 2005-12-02 | 2007-10-18 | 주식회사 케미랜드 | Powder type cosmetic composition |
WO2010148180A2 (en) * | 2009-06-19 | 2010-12-23 | U.S. Cosmetics Corporation | Cosmetic compositions and methods for enhanced uv protection |
KR101346792B1 (en) * | 2010-09-03 | 2014-01-02 | 주식회사 엘지생활건강 | Cosmetic composition for improving skin wrinkle comprising polyethoxylated retinamide in nanoliposome comprising UV absorber |
KR101314100B1 (en) | 2011-07-12 | 2013-10-04 | (주)에이씨티 | Stabilizing method of an unstable retinol using nanoparticles of silica coated lipid monolayer shell and biodegradable polymer core and cosmetic composition containing the same |
KR102195983B1 (en) * | 2019-08-28 | 2020-12-30 | 주식회사 비제이바이오켐 | Method for producing a cosmetic composition comprising silica ceramide composite |
-
2021
- 2021-06-29 KR KR1020210084952A patent/KR102697264B1/en active IP Right Grant
-
2022
- 2022-06-22 CN CN202210710367.7A patent/CN115531230A/en active Pending
- 2022-06-24 TW TW111123770A patent/TW202317065A/en unknown
- 2022-06-27 JP JP2023580832A patent/JP2024525049A/en active Pending
- 2022-06-27 WO PCT/KR2022/009120 patent/WO2023277479A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023277479A1 (en) | 2023-01-05 |
KR102697264B1 (en) | 2024-08-22 |
CN115531230A (en) | 2022-12-30 |
KR20230001874A (en) | 2023-01-05 |
TW202317065A (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20130030093A (en) | Composition for skin external application containing ceramide | |
EP0452202B1 (en) | Aqueous cosmetic or dermo-pharmaceutical composition containing in suspension hydrated spheroids of hydrophilic lipidic substance | |
TW570807B (en) | Oil-in-water type emulsified composition | |
EP2139453B1 (en) | Polyaphron topical composition with vitamin d | |
JP2003527411A (en) | Method for preparing a high pressure / high shear dispersion containing a physiologically active ingredient | |
WO2001085156A1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
US6054138A (en) | Stabilized pseudo-emulsions and their preparation process | |
AU2018435421A1 (en) | Topical composition | |
EP3576716B1 (en) | Topical composition | |
JP2024525049A (en) | Surface-modified retinoid-loaded porous silica | |
EP3708141A1 (en) | Method for treating hair with a cosmetic composition comprising particles of hydrophobic silica aerogel and a specific acrylic thickening polymer | |
JPH01249714A (en) | Skin cosmetic | |
JP2009084243A (en) | Horny layer hyaluronic acid production accelerator and external dermatological preparation, cosmetic, and quasi-drug containing horny layer hyaluronic acid production accelerator | |
JP4300105B2 (en) | Antioxidant | |
JPH08301745A (en) | Skin cosmetic | |
JP2006282536A (en) | Super oxide-eliminating agent, free radical-eliminating agent, hydrogen peroxide-eliminating agent and external preparation for skin | |
JPS63215611A (en) | Cosmetic | |
KR20130138563A (en) | Antiaging cosmetic composition comprising photoreactive chitosan derivatives and epidermal growth factor immobilized thereon | |
JPS58128310A (en) | Skin conditioner | |
KR102294435B1 (en) | A cosmetic composition | |
RU2315592C2 (en) | Active cream for normal and mixed skin | |
RU2635524C1 (en) | Cosmetic cream | |
RU2150263C1 (en) | Night nutrient cream | |
JPH1192331A (en) | Skin preparation for external use | |
RU2200001C2 (en) | Cream for skin |